MPLT MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. (MPLT) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is a loss of $1.27 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -2.4% since its last earnings release on August 13, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About MapLight Therapeutics, Inc.
MapLight Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on improving the lives of patients suffering from debilitating central nervous system disorders. The company's lead product candidate includes ML-007C-MA. MapLight Therapeutics Inc. is based in SAN FRANCISCO.
Sector
Healthcare
Industry
Biotechnology